2020 Cerebral Palsy Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

2020 Cerebral Palsy Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

  • February 2020 •
  • 46 pages •
  • Report ID: 5863922 •
  • Format: PDF
The 2020 Cerebral Palsy pipeline report presents a comprehensive overview of the research and development of Cerebral Palsy drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Four drugs in Pre-clinical phase, and two drugs in Phase 3

As of February 2020, the Cerebral Palsy pipeline remains robust with 7 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Cerebral Palsy treatment. Diverse types of targeted therapies are being explored through clinical trials including SNAP-25 (synaptosomal associated protein) inhibitor; Vesicular monoamine transporter 2 inhibitors.

The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Cerebral Palsy drug development history, latest news, and other developments.

It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.

Publisher Expertise
Our online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.

• The report scope comprises of both pre-clinical phase and clinical phase development drugs for Cerebral Palsy development
• Cerebral Palsy pipeline compounds and molecules under study by both large scale and small companies are included in the report
• Cerebral Palsy pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
• Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
• Further, orphan drug status, fast track designation, different grants awarded and special status for Cerebral Palsy pipeline candidates included
• Business overview and snapshot of all companies involved in Cerebral Palsy pipeline are included
• Latest market and pipeline developments are provided in the report

Cerebral Palsy pipeline companies included in the report are- Baylx Inc, CytoDel Inc, Hope Biosciences LLC, Kashiv BioSciences LLC, Meridigen Biotech Co Ltd, Mylan NV, Teva Pharmaceutical Industries Ltd

Cerebral Palsy pipeline drugs profiled in the report include- Cyto-012, HB-adMSC, K128, UMC-11910, onabotulinumtoxinA , TEV-50717 (deutetrabenazine), BX-U007